Abstract

The MarketScan Commercial Database (previously called the 'MarketScan Database') contains real-world data for healthcare research and analytics to examine health economics and treatment outcomes.

This page also contains the MarketScan Commercial Lab Database starting in 2018.

Starting in 2026, there will be a data access fee for using the full dataset. Please refer to the 'Usage Notes' section of this page for more information.

Methodology

MarketScan Research Databases are a family of data sets that fully integrate many types of data for healthcare research, including:

• De-identified records of more than 188 million patients (medical, drug and dental)

%3C!-- --%3E

• Laboratory results

%3C!-- --%3E

• Hospital discharges

%3C!-- --%3E

The MarketScan Databases track millions of patients throughout the healthcare system. The data are contributed by large employers, managed care organizations, hospitals, EMR providers, and Medicare.

Usage

This page contains the MarketScan Commercial Database.

We also have the following on other pages:

• The MarketScan Medicare Supplemental Database
• The MarketScan Dental Database
• The MarketScan Benefit Plan Design data
• MarketScan Redbook (The MarketScan Code Reference Book)

%3C!-- --%3E

**Starting in 2026, there will be a data access fee for using the full dataset **(though the 1% sample will remain free to use). The pricing structure and other **relevant information can be found in this **FAQ Sheet.

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

Section 2

Metadata access is required to view this section.

Section 3

Metadata access is required to view this section.

Usage FAQs (Answers provided in User Guide starting on page 56)

Metadata access is required to view this section.

Abstract

The MarketScan Medicare Supplemental Database provides detailed cost, use and outcomes data for healthcare services performed in both inpatient and outpatient settings.

It Include Medicare Supplemental records for all years, and Medicare Advantage records starting in 2020. This page also contains the MarketScan Medicare Lab Database starting in 2018.

Starting in 2026, there will be a data access fee for using the full dataset. Please refer to the 'Usage Notes' section of this page for more information.

Methodology

MarketScan Research Databases are a family of data sets that fully integrate many types of data for healthcare research, including:

• De-identified records of more than 250 million patients (medical, drug and dental)

%3C!-- --%3E

• Laboratory results

%3C!-- --%3E

• Hospital discharges

%3C!-- --%3E

The MarketScan Databases track millions of patients throughout the healthcare system. The data are contributed by large employers, managed care organizations, hospitals, EMR providers and Medicare.

Usage

This page contains the MarketScan Medicare Database.

We also have the following on other pages:

• The MarketScan Commercial Database
• The MarketScan Dental Database
• The MarketScan Benefit Plan Design data
• MarketScan Redbook (The MarketScan Code Reference Book)

%3C!-- --%3E

**Starting in 2026, there will be a data access fee for using the full dataset **

(though the 1% sample will remain free to use). The pricing structure and other

**relevant information can be found in this **FAQ Sheet.

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

Section 2

Metadata access is required to view this section.

Section 3

Metadata access is required to view this section.

Abstract

The MarketScan Dental Database is a standalone product that corresponds with and is linkable to a given year and version of the IBM MarketScan Commercial Claims and Encounters Database and the MarketScan Medicare Supplemental and Coordination of Benefits Database. Currently, data is available for the years: 2005 - 2023. In order to view the MarketScan Dental user guide or data dictionary, you must have data access to this dataset.

Usage

In addition to what's on this page, we also have:

• The MarketScan Commercial Database
• The MarketScan Medicare Supplemental Database
• The MarketScan Benefit Plan Design data

%3C!-- --%3E

• MarketScan Redbook (The MarketScan Code Reference Book)

%3C!-- --%3E

**Starting in 2026, there will be a data access fee for using the full dataset **(though the 1% sample will remain free to use). The pricing structure and other **relevant information can be found in this **FAQ Sheet.

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

Section 3

Metadata access is required to view this section.

Section 4

Metadata access is required to view this section.

Section 5

Metadata access is required to view this section.

Section 6

Metadata access is required to view this section.

This is a peer-reviewed supplementary table for the article 'Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: MG treatment definitionsAim: There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM MarketScan database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period. Results: Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MGrelated healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations. Conclusion: Despite utilization of current treatments for MG,MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.

Software suite of proprietary databases that contain one of longest running and largest collection of privately and publicly insured, de identified patient data in USA. Family of data sets that fully integrate many types of data for healthcare research.

This dataset is a de-identified summary table of prevalence rates for vision and eye health data indicators from the 2016 MarketScan® Commercial Claims and Encounters Data (CCAE) is produced by Truven Health Analytics, a division of IBM Watson Health. The CCEA data contain a convenience sample of insurance claims information from person with employer-sponsored insurance and their dependents, including 43.6 million person years of data. Prevalence estimates are stratified by all available combinations of age group, gender, and state. Detailed information on VEHSS MarketScan analyses can be found on the VEHSS MarketScan webpage (cdc.gov/visionhealth/vehss/data/claims/marketscan.html). Information on available Medicare claims data can be found on the IBM MarketScan website (https://marketscan.truvenhealth.com). The VEHSS MarketScan summary dataset was last updated November 2019.

Crude and age–standardized pregnancy rates per 1,000 person-year of females aged 13–19 years, overall and according to mental disorder type.

Study sample baseline characteristics at index admission for Clostridium difficile compared with all Truven hospital admission claims in 2011.

Abstract

Lookup table (Code Reference Book) for MarketScan

Usage

Redbook is cumulative, so the most recent Redbook can be used for all years.

In addition to what's on this page, we also have:

• The MarketScan Commercial Database

%3C!-- --%3E

• The MarketScan Medicare Supplemental Database
• The MarketScan Dental Database
• The MarketScan Benefit Plan Design data

%3C!-- --%3E

**Starting in 2026, there will be a data access fee for using the full dataset **

(though the 1% sample will remain free to use). The pricing structure and other

**relevant information can be found in this **FAQ Sheet.

Before Manuscript Submissions

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Data Documentation

Data access is required to view this section.

Annual counts of individuals enrolled in MarketScan Research Databases and counts of patients with ≥1 AMI diagnosis according to ICD-CM codes received in any healthcare setting (2014–2017).

Abstract

We had to delete V3 of MarketScan because of some unusual circumstances with the formats of some of the files we were sent (to prevent the duplication of records). V3.1 contains all of the info that was in V3, however V3.1 has 2022 data & a slightly different version of the 2021 data. The data on this page is the version of the 2021 data that was in V3. Our purpose in posting this is to enable researchers who completed analyses on V3 to replicate their work by combining the data here with the data on the main page.

FOR THE MAJORITY OF RESEARCHERS, however, we strongly recommend using V3.1, and ignoring this page, as it will be irrelevant for most research going forward. (Rule of thumb: If you are unsure whether you need the data on this page, then you probably don't need it.)

Usage

To recreate V3 of the data, use the data for 2020 and earlier that is on the main MarketScan Databases page, and combine it with the data on this page. That will give you the *exact *same data that was in V3.

The data documentation on the main MarketScan page also applies to the data on this page.

**Starting in 2026, there will be a data access fee for using the full dataset **

(though the 1% sample will remain free to use). The pricing structure and other

**relevant information can be found in this **FAQ Sheet.

How is the data on this page different from the 2021 data on the main MarketScan page?

Metadata access is required to view this section.

Abstract

The MarketScan Benefit Plan Design Database represents the benefit plans for large employers whose claims data comprise portions of the MarketScan Commercial Claims and Encounters Database. Currently, data is available for 2013 - 2023.

Starting in 2026, there will be a data access fee for using the full dataset. Please refer to the 'Usage Notes' section of this page for more information.

Usage

In addition to what's on this page, we also have:

• The MarketScan Commercial Database
• The MarketScan Medicare Supplemental Database
• The MarketScan Dental Database

%3C!-- --%3E

• MarketScan Redbook (The MarketScan Code Reference Book)

%3C!-- --%3E

**Starting in 2026, there will be a data access fee for using the full dataset **

(though the 1% sample will remain free to use). The pricing structure and other

**relevant information can be found in this **FAQ Sheet.

Before Manuscript Submission

All manuscripts (and other items you'd like to publish) must be submitted to

support@stanfordphs.freshdesk.com for approval prior to journal submission.

We will check your cell sizes and citations.

For more information about how to cite PHS and PHS datasets, please visit:

https:/phsdocs.developerhub.io/need-help/citing-phs-data-core

Documentation

Data access is required to view this section.

Characteristics of pregnancies from patients with pre-existing hypertension, MarketScan® commercial claims databases, 2011–2020.

Patterns of dose titration.

Cox proportional hazards model for factors associated with treatment discontinuation or switch.

The MarketScan health claims database is a compilation of nearly 110 million patient records with information from more than 100 private insurance carriers and large self-insuring companies. Public forms of insurance (i.e., Medicare and Medicaid) are not included, nor are small (< 100 employees) or medium (1000 employees). We excluded the relatively few (n=6735) individuals over 65 years of age because Medicare is the primary insurance of U.S. adults over 65. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Gray, C., D. Lobdell, K. Rappazzo, Y. Jian, J. Jagai, L. Messer, A. Patel, S. Deflorio-Barker, C. Lyttle, J. Solway, and A. Rzhetsky. Associations between environmental quality and adult asthma prevalence in medical claims data. ENVIRONMENTAL RESEARCH. Elsevier B.V., Amsterdam, NETHERLANDS, 166: 529-536, (2018).

These are peer-reviewed supplementary materials for the article 'Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Mean (SD) number of inpatient admissions per patient in individuals with SMA in the 12 months before and after nusinersen treatment. Mean (SD) number of days spent in hospital per patient in individuals with SMA in the 12 months before and after nusinersen treatment.Supplementary Figure 2: Mean (SD) ED visits and costs per patient in individuals with SMA in the 12 months before and after nusinersen treatment.Supplementary Table 1: Patient baseline characteristics of cohorts aligned with steps of patient selection criteria (who were ultimately excluded) in comparison to final cohort.Aim: Nusinersen, administered by intrathecal injection at a dose of 12 mg, is indicated across all ages for the treatment of spinal muscular atrophy (SMA). Evidence on real-world healthcare resource use (HRU) and costs among patients taking nusinersen remains limited. This study aimed to evaluate real-world HRU and costs associated with nusinersen use through US claims databases. Patients & methods: Using the Merative™ MarketScan R ? Research Databases, patients with SMA receiving nusinersen were identified from commercial (January 2017 to June 2020) and Medicaid claims (January 2017 to December 2019). Those likely to have complete information on the date of nusinersen initiation and continuous enrollment 12 months pre- and post-index (first record of nusinersen treatment) were retained. Number and costs (US$ 2020) of inpatient admissions and emergency department (ED) visits, unrelated to nusinersen administration, were evaluated for 12 months pre- and post-nusinersen initiation and stratified by age: pediatric (

Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral ADT, with limited real-world data on therapy persistence and adherence. This retrospective study evaluates persistence and adherence of relugolix, degarelix, and GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using data from the IBM MarketScan Research Database (Jan 2017 - Dec 2022). The IBM MarketScan Research Database (1 January 2017 - 31 December 2022) was used for enrollment history and claims. ADT adherence was measured by the proportion of days covered (PDC) at 3, 6, and 12 months, calculated as days on ADT divided by period duration. Kaplan-Meier analysis assessed treatment persistence by measuring time to treatment discontinuation. Relugolix had higher adherence (PDC ≥ 80%) at 12 months (60.8%) compared to degarelix (13.0%) and GnRH agonists (46.3%). Median time to discontinuation was also longer for relugolix (13.5 months) than degarelix (3.1 months) and GnRH agonists (8.8 months). Persistence and adherence rates were higher in metastatic prostate cancer. Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles. Prostate cancer is the second most common cancer among men in the US. Androgen deprivation therapy (ADT), a key treatment for advanced prostate cancer, lowers testosterone levels, a hormone that helps prostate cancer grow. ADT includes injectable gonadotropin-releasing hormone (GnRH) receptor agonists like leuprolide, which initially raise testosterone before lowering it, and antagonists like degarelix, (injectable) and relugolix (oral), which rapidly lower testosterone. A large clinical trial (phase III) showed relugolix rapidly and consistently lowered testosterone, with similar side effects to leuprolide but fewer major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and death from any cause). There is limited published real-world data, including healthcare information like medical records and insurance claims, on how well patients stay on treatment (persistence) and take their medication as prescribed (adherence) for different forms of ADT, especially oral relugolix. Data from the IBM MarketScan Research Database (January 2017 to December 2022) was used to compare persistence and adherence among patients taking oral relugolix, injectable degarelix, and injectable GnRH receptor agonists. Patients taking relugolix had a higher rate of adherence to their treatment (60.8%) after 12 months versus those receiving injectable degarelix (13.0%) and other injectables, GnRH receptor agonists (46.3%). Patients on relugolix also stayed on their treatment longer (13.5 months) compared to those on injectable degarelix (3.1 months) and GnRH receptor agonists (8.8 months). These results were especially notable in patients with metastatic prostate cancer. This study demonstrates favorable persistence and adherence rates with oral relugolix in patients receiving ADT for advanced prostate cancer.

This table provides the data for age and gender comparisons of the three different treatment modalities for keloid management using the Truven Marketscan Insurance claims database. The average treatment length and average number of visits are reported with their respective median and 25th and 75th percentiles.

Data are number or percent (95% CI). p-Value is for the difference between the two groups.Annual frequency of asthma-related emergency room visits and asthma-related hospitalizations: comparing adenotonsillectomy to no adenotonsillectomy.